TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20364899

Group type: EXPERIMENTAL
Intervention: Attentional bias reduction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 48
Study: 18596863

Group type: EXPERIMENTAL
Intervention: Use of electronic medical records (EMRs) for performance measurement and improvement
Number of subjects: 0
Study: 16875153

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily for 4 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12828751

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 10817857

Group type: EXPERIMENTAL
Intervention: Cyanotic congenital heart disease patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Noncyanotic controls
Number of subjects: 22
Study: 9017562

Group type: EXPERIMENTAL
Intervention: Stage-based telephone counseling (3 post-treatment calls)
Number of subjects: 288
Study: 1625002

Group type: EXPERIMENTAL
Intervention: Special intervention group (soft-tissue examination, advice to quit ST, self-help materials, short video, encouragement to set a quit date)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 518
Study: 6134549

Group type: EXPERIMENTAL
Intervention: Proquazone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Opiate analgesics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30753443

Group type: EXPERIMENTAL
Intervention: Prediction model for TPC risk using multivariable logistic regression.
Number of subjects: 440

Group type: COMPARATOR
Intervention: Validation cohort of the prediction model.
Number of subjects: 440
Study: 29742656

Group type: EXPERIMENTAL
Intervention: 1% lidocaine paracervical block
Number of subjects: 93
Study: 27596284

Group type: EXPERIMENTAL
Intervention: 30 g/day of pecan nuts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 ml/day of olive oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 25730928

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) combined with gaseous carbon dioxide baths and infrared laser therapy
Number of subjects: 40
Study: 23110412

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 300
Study: 20303789

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation >1000 microg
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation <1000 microg
Number of subjects: 1846
Study: 17584547

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Various definitions of bleeding
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Standardized bleeding definitions
Number of subjects: 3000
Study: 15813818

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg, two doses, 1 week apart)
Number of subjects: 40
Study: 12014211

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AP) with orally absorbable antibiotics: 250 mg ciprofloxacin twice a day, 150 mg roxithromycin twice a day, 50 mg fluconazole once a day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no antimicrobial prophylaxis)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AP)
Number of subjects: 95
Study: 10468294

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b (IFN-alpha-2b) intravenous: 20 MIU m(−2), 5 days a week for 4 weeks; subcutaneous: 10 MIU m(−2), 3 times a week for 11 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b (IFN-alpha-2b)
Number of subjects: 36
Study: 8725042

Group type: EXPERIMENTAL
Intervention: Continuous flow bladder irrigation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Suprapubic flow irrigation (without suction pump)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Without continuous flow irrigation
Number of subjects: 120
Study: 2112640

Group type: COMPARATOR
Intervention: Control Formula (CF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Study Formula (SF)
Number of subjects: 23
Study: 538418

Group type: EXPERIMENTAL
Intervention: Guaiacolic ester of acetylsalicylic acid (ASA-G)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29742522

Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) training over a 6-month period
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 120
Study: 30225786

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioural approach (NSEB)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE) and Neck-specific exercise with a behavioural approach (NSEB)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Physical activity prescription (PPA)
Number of subjects: 216
Study: 28486634

Group type: EXPERIMENTAL
Intervention: Standardised patient education programme
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 248
Study: 26017658

Group type: EXPERIMENTAL
Intervention: AccuCirc device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mogen clamp
Number of subjects: 0
Study: 23649968

Group type: EXPERIMENTAL
Intervention: Limaçon shapes with varying curvature presented in various 3D orientations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elliptical hoops with flattened regions
Number of subjects: 0
Study: 21187303

Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extensively protein hydrolysate formula (PHF)
Number of subjects: 0
Study: 19717853

Group type: EXPERIMENTAL
Intervention: Topical insulin (10 units, 0.1 cc) applied twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (1 cc saline 0.9% for each 10 cm2 of wound) applied twice daily
Number of subjects: 45
Study: 18520804

Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT) 200 mg/m2 twice daily from day 1 through 14 plus gemcitabine 900 mg/m2 on days 8 and 15, repeated every 3 or 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT) and gemcitabine combination chemotherapy
Number of subjects: 40
Study: 16290983

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 327

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 327
Study: 12017502

Group type: EXPERIMENTAL
Intervention: 10-minute massage
Number of subjects: 78

Group type: COMPARATOR
Intervention: 10 minutes of quiet time with a massage therapist (Control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 78
Study: 10223230

Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) testing using six microsatellite markers (D2S123, D3S1029, D3S1611, TP53, Mfd26, and Mfd36)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) testing in tumors of the distal colon and rectum
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no MSI testing mentioned)
Number of subjects: 47
Study: 8527689

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of talinolol (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of talinolol (50 mg)
Number of subjects: 12
Study: 2550647

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 130

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 130
Study: 137218

Group type: EXPERIMENTAL
Intervention: Aminophylline (0.24 g i.v.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diprophylline (0.28 g i.v.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (0.005 mg i.v.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.08 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 24
Study: 29451036

Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate (CS) 800 mg/day
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 27834579

Group type: EXPERIMENTAL
Intervention: Resistance Tubing (RT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wobble Board (WB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both RT and WB
Number of subjects: 14
Study: 26671226

Group type: EXPERIMENTAL
Intervention: CHU9D instrument (utility-based HRQOL)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: PedsQL instrument (general HRQOL)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Construct validity of CHU9D
Number of subjects: 1334
Study: 24349496

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (protein/energy/vitamins) among undernourished mothers
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy/vitamins or vitamins only)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 283
Study: 22003157

Group type: EXPERIMENTAL
Intervention: Agility and perturbation training with standard exercise therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 183
Study: 18433755

Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic agents
Number of subjects: 574

Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 574

Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Insulin therapy (in vitro)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Insulin therapy (before and after treatment)
Number of subjects: 574
Study: 16988562

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (3 mg in 1 mL saline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (50 mg twice daily for 1 week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study: 12636950

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (33 or 133 mg) supplementation from eggs until parturition
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study: 10825311

Group type: EXPERIMENTAL
Intervention: Ornipressin started at 1 IU/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Norepinephrine started at 0.04 microg x kg(‐1) x min(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dopamine started at 2 microg x kg(‐1) x min(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (15 patients without hypotension)
Number of subjects: 60
Study: 8851608

Group type: COMPARATOR
Intervention: Atevirdine alone (treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Concurrent administration of didanosine and atevirdine (treatment C)
Number of subjects: 12
Study: 1531328

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6337198

Group type: EXPERIMENTAL
Intervention: Aqueous solution of mixed-grass extract
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Formaldehyde-modified mixed-grass extract (allergoid)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Histamine solution (placebo)
Number of subjects: 50
Study: 30269312

Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ) 400 mg for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chloroquine (CQ) 1500 mg for 3 days then Primaquine (PQ) 15 mg for 14 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chloroquine (CQ) / Primaquine (PQ)
Number of subjects: 70
Study: 30055170

Group type: EXPERIMENTAL
Intervention: FOB-Gold (Sentinel, Milan, Italy)
Number of subjects: 42179

Group type: COMPARATOR
Intervention: OC-Sensor (Eiken Chemical, Tokyo Japan)
Number of subjects: 42179

Group type: EXPERIMENTAL
Intervention: FOB-Gold
Number of subjects: 42179

Group type: COMPARATOR
Intervention: OC-Sensor
Number of subjects: 42179

Group type: EXPERIMENTAL
Intervention: FOB-Gold vs OC-Sensor
Number of subjects: 42179
Study: 27410490

Group type: EXPERIMENTAL
Intervention: ASP2408 3.0 mg/kg subcutaneously every 4 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ASP2408 3.0 mg/kg subcutaneously every 2 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ASP2408 (various doses)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ASP2408
Number of subjects: 88
Study: 24496491

Group type: EXPERIMENTAL
Intervention: Estimation task (duration of a presented sound)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation task (length of a travelled distance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Production task (terminate a sound after a specified duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Production task (cover a specified distance)
Number of subjects: 0
Study: 22237225

Group type: EXPERIMENTAL
Intervention: 16G needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: 18G needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both needles
Number of subjects: 50
Study: 20402591

Group type: EXPERIMENTAL
Intervention: Azithromycin 2.0 g orally as a single dose
Number of subjects: 517

Group type: COMPARATOR
Intervention: Benzathine penicillin G 2.4 million units intramuscularly
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 517
Study: 18024508

Group type: EXPERIMENTAL
Intervention: Diabetes passport intervention
Number of subjects: 993

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 993
Study: 16444089

Group type: EXPERIMENTAL
Intervention: Nasal dilator strips
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Local decongestants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Local decongestant followed by nasal dilator
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 23

Group type: COMPARATOR
Intervention: No application
Number of subjects: 23

Group type: COMPARATOR
Intervention: Local decongestant followed by placebo strip
Number of subjects: 23
Study: 11890175

Group type: EXPERIMENTAL
Intervention: Team-oriented training using cognitive mapping technique (n = 29)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Didactic, informational training (n = 23)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No-training control group (n = 17)
Number of subjects: 420
Study: 11910671

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavone extract
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 160 mg isoflavone extract
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7729400

Group type: EXPERIMENTAL
Intervention: Latex gloves of 0.83 mm thickness
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thinner latex gloves (0.21 mm, 0.51 mm, 0.65 mm, 0.76 mm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bare hand
Number of subjects: 20
Study: 2393283

Group type: EXPERIMENTAL
Intervention: Cefprozil under fasting conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefprozil after food intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefaclor under fasting conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefaclor after food intake
Number of subjects: 12
Study: 7079142

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous morphine
Number of subjects: 20
Study: 31096724

Group type: EXPERIMENTAL
Intervention: SOC+C+P (chlorpromazine 12.5 mg BID + promethazine 12.5 mg BID or chlorpromazine 25 mg BID + promethazine 25 mg BID) for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SOC+C+P
Number of subjects: 64
Study: 29333947

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP∼T
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB/PRP∼T
Number of subjects: 2
Study: 26717552

Group type: EXPERIMENTAL
Intervention: Lifetime cannabis use disorder (CUD)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: History of multiple psychiatric disorders
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lifetime alcohol use disorder
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: More frequent attempts to quit smoking tobacco
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lower self‐efficacy about weight management after quitting smoking tobacco
Number of subjects: 273
Study: 25386018

Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Case-Based Learning (CBL)
Number of subjects: 174
Study: 22563773

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 20228981

Group type: EXPERIMENTAL
Intervention: Restorations with marginal beveling
Number of subjects: 13

Group type: COMPARATOR
Intervention: Restorations without bevel (butt joint)
Number of subjects: 13
Study: 17481803

Group type: EXPERIMENTAL
Intervention: Mini-hystroscopy (Group A)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Traditional hystroscopy (Group B)
Number of subjects: 950
Study: 16134997

Group type: EXPERIMENTAL
Intervention: Desloratadine (DL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11923030

Group type: EXPERIMENTAL
Intervention: Herbal therapies
Number of subjects: 15000000
Study: 9472506

Group type: EXPERIMENTAL
Intervention: Direct offer of HIV testing
Number of subjects: 3024

Group type: COMPARATOR
Intervention: Control group (no information or direct offer)
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Information provided (leaflet and discussion)
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 3024
Study: 7629460

Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness (thinnest quartile)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness (fattest quartile)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Maximum reported body mass index (highest quartile)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Reported body mass index aged 21 years (highest quartile)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Maximum reported body mass index and reported body mass index aged 21 years
Number of subjects: 323
Study: 1973770

Group type: EXPERIMENTAL
Intervention: Community-based intervention including mass education about childhood pneumonia and case-management by trained health workers using co-trimoxazole.
Number of subjects: 10123
Study: 32615

Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg three times daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral ampicillin 1000 mg three times daily
Number of subjects: 48
Study: 31064563

Group type: EXPERIMENTAL
Intervention: COPD self-management intervention
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Household member secondary outcomes
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Inclusion of household member QALYs in ICER
Number of subjects: 153
Study: 28566169

Group type: EXPERIMENTAL
Intervention: DLPFC stimulation (2mA, 20min, anodal stimulation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M1 stimulation (2mA, 20min, anodal stimulation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study: 25986639

Group type: EXPERIMENTAL
Intervention: Booklet-based vestibular rehabilitation with expert telephone support
Number of subjects: 33

Group type: COMPARATOR
Intervention: Booklet-based vestibular rehabilitation without expert telephone support
Number of subjects: 33
Study: 23866694

Group type: EXPERIMENTAL
Intervention: High bicarbonate mineral water (SY)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low mineral water (Control)
Number of subjects: 12
Study: 21034681

Group type: EXPERIMENTAL
Intervention: ADHD group (n = 116)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (n = 146)
Number of subjects: 262
Study: 19821718

Group type: EXPERIMENTAL
Intervention: CUF2 herbal formula (0.619-g capsule daily for 6 months)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 16423088

Group type: EXPERIMENTAL
Intervention: Esomeprazole 2 x 40 mg, levofloxacin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ELA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Esomeprazole 2 x 20 mg, clarithromycin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ECA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 61
Study: 15233698

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg on-demand treatment
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 11764011

Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 10633220

Group type: EXPERIMENTAL
Intervention: 1 IU/kg rhGH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg rhGH
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1 IU/kg rhGH and 0.5 IU/kg rhGH
Number of subjects: 32
Study: 8866880

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1516463

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg b.i.d. for 7 days
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg b.i.d. for 10 days
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg b.i.d. for 10 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin for 10 days
Number of subjects: 148
Study: 6661468

Group type: EXPERIMENTAL
Intervention: Low-dose naloxone infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose naloxone infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 12